NO20040598L - 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter. - Google Patents

5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.

Info

Publication number
NO20040598L
NO20040598L NO20040598A NO20040598A NO20040598L NO 20040598 L NO20040598 L NO 20040598L NO 20040598 A NO20040598 A NO 20040598A NO 20040598 A NO20040598 A NO 20040598A NO 20040598 L NO20040598 L NO 20040598L
Authority
NO
Norway
Prior art keywords
parathyroid hormone
oral delivery
cnac
delivery agent
hormone fragments
Prior art date
Application number
NO20040598A
Other languages
English (en)
Other versions
NO328069B1 (no
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040598L publication Critical patent/NO20040598L/no
Publication of NO328069B1 publication Critical patent/NO328069B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20040598A 2001-08-17 2004-02-10 Farmasoytisk sammensetning for oral avlevering omfattende paratyreoidhormonfragmenter og 5-CNAC, samt anvendelse av sammensetningen for fremstilling av et medikament for behandling av benforstyrrelser. NO328069B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (2)

Publication Number Publication Date
NO20040598L true NO20040598L (no) 2004-02-10
NO328069B1 NO328069B1 (no) 2009-11-23

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040598A NO328069B1 (no) 2001-08-17 2004-02-10 Farmasoytisk sammensetning for oral avlevering omfattende paratyreoidhormonfragmenter og 5-CNAC, samt anvendelse av sammensetningen for fremstilling av et medikament for behandling av benforstyrrelser.

Country Status (26)

Country Link
US (4) US20040242478A1 (no)
EP (1) EP1420827B8 (no)
JP (2) JP4959917B2 (no)
KR (1) KR20040030120A (no)
CN (1) CN1279981C (no)
AT (1) ATE443527T1 (no)
AU (1) AU2002333443C1 (no)
BR (1) BRPI0211932B1 (no)
CA (1) CA2453646C (no)
CO (1) CO5560586A2 (no)
CY (1) CY1109661T1 (no)
DE (1) DE60233803D1 (no)
DK (1) DK1420827T3 (no)
EC (1) ECSP044961A (no)
ES (1) ES2333587T3 (no)
HU (1) HUP0401441A3 (no)
IL (2) IL159714A0 (no)
MX (1) MXPA04001418A (no)
NO (1) NO328069B1 (no)
NZ (1) NZ531018A (no)
PL (1) PL210258B1 (no)
PT (1) PT1420827E (no)
RU (1) RU2322256C2 (no)
SI (1) SI1420827T1 (no)
WO (1) WO2003015822A1 (no)
ZA (1) ZA200400242B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
RU2322256C2 (ru) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AU2004262906B2 (en) 2003-07-23 2008-04-03 Nordic Bioscience A/S Use of calcitonin in osteoarthritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN103356997A (zh) * 2006-08-31 2013-10-23 诺瓦提斯公司 用于口服递送的包含hgh 的药物组合物
WO2008109385A2 (en) * 2007-03-02 2008-09-12 Novartis Ag Oral administration of a calcitonin
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
EP3256114A4 (en) * 2015-02-09 2018-11-21 Entera Bio Ltd. Treatment of osteoporosis
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
EP1093819B1 (en) * 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU1918300A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Amino-terminal modified parathyroid hormone (pth) analogs
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
RU2322256C2 (ru) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
CA2529604C (en) * 2003-07-11 2012-05-08 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
WO2003015822A1 (en) 2003-02-27
JP2005501852A (ja) 2005-01-20
SI1420827T1 (sl) 2010-01-29
AU2002333443C1 (en) 2009-10-08
KR20040030120A (ko) 2004-04-08
AU2002333443B2 (en) 2006-06-29
PT1420827E (pt) 2009-12-15
BR0211932A (pt) 2004-10-26
JP4959917B2 (ja) 2012-06-27
NZ531018A (en) 2006-03-31
NO328069B1 (no) 2009-11-23
HUP0401441A2 (hu) 2004-12-28
EP1420827B8 (en) 2009-12-23
US20060217313A1 (en) 2006-09-28
PL365388A1 (en) 2005-01-10
MXPA04001418A (es) 2004-05-27
US20090264367A1 (en) 2009-10-22
CA2453646A1 (en) 2003-02-27
IL159714A (en) 2010-12-30
RU2322256C2 (ru) 2008-04-20
ZA200400242B (en) 2004-11-18
IL159714A0 (en) 2004-06-20
PL210258B1 (pl) 2011-12-30
CO5560586A2 (es) 2005-09-30
HUP0401441A3 (en) 2012-09-28
EP1420827B1 (en) 2009-09-23
BRPI0211932B1 (pt) 2016-12-06
CN1279981C (zh) 2006-10-18
CN1543357A (zh) 2004-11-03
CY1109661T1 (el) 2014-08-13
US20120088725A1 (en) 2012-04-12
US20040242478A1 (en) 2004-12-02
DE60233803D1 (de) 2009-11-05
DK1420827T3 (da) 2009-12-21
JP2009242410A (ja) 2009-10-22
ES2333587T3 (es) 2010-02-24
ECSP044961A (es) 2004-03-23
ATE443527T1 (de) 2009-10-15
CA2453646C (en) 2008-09-30
RU2004107899A (ru) 2005-05-10
EP1420827A1 (en) 2004-05-26
US9272040B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
IL220043A0 (en) Methods for producing ??-galactosidase a compositions
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
GT199700009AA (es) Terapia combinada para la osteoporosis
DE60218842D1 (de) Orale verabreichung von parathyroidhormon und calcitonin
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL370361A1 (en) Alkyl urea retinoid agonists i
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
PL370459A1 (en) Substituted urea retinoid agonists ii
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
HUP0203741A2 (hu) Eljárás oszteoporózis kezelésére
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
ITMI20031303A1 (it) Composizioni per impianti sottocutanei contenenti almeno un ormone steroideo per la terapia ormonale sostitutiva e per la contraccezione.
UY26651A1 (es) Terapia combinada para la osteoporosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees